OrbiMed-led the Series B $105m investment in AbCellera, a privately held biotech with a drug discovery platform that searches and analyzes natural immune systems to find antibodies. “Drug development takes too long, fails too often, and costs too much. With the backing of visionary investors, we will double-down on our strategy of making long-term investments in technology and teams that are needed to put drug development on the fast track,” Ph.D. Carl Hansen, AbCellera CEO.